Vaccines Getting Some Attention From U.S. Government Tuesday, 06 October 2009
Regions
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland&Labrador
Northwest Territories
Nova Scotia
Nunavut
Ontario
Prince Edward Island
Quebec
Saskatchewan
Yukon Territory
Other
Non-Canadian PRs



Privacy Policy

BEERLE.com - Search with pleasure :-))) BEERLE.com



CEL-SCI's H1N1 Treatment and Vaccines Getting Some Attention From U.S. Government
Posted by mincho2008
Thursday, 17 September 2009
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation (NYSE Amex: CVM).
According to the report, the company had been in discussions over the past several days with multiple government groups interested in expediting CEL-SCI's H1N1 efforts.

Contacted about the developments, CEL-SCI's CEO Geert Kersten made it clear that he was not able to comment on the nature or scope of any of these meetings.

When asked about recent SEC filings that shows that the company has been working not only influenza vaccines using their patented L.E.A.P.S.™ technology, but also some treatment options for already infected patients, Kersten shed more light on the situation:

"Everything here is done by collaboration. That's the idea of the team. It may have been someone's comment leading to the input of others and that took us down the road of the mutated virus and then we said, 'Well, if we can work on the mutated virus, who is actually addressing the issue of all those people lying in an ICU today, fighting for their lives for a week or ten days?' And then we figured out that using the same approach we ought to be able to help them improve their chances of survival.

"Somewhere along the way, it was like a Eureka moment," explains Kersten. "We've got to help these people. Everybody's focus is on vaccines and they're having all kinds of problems with the vaccines, but there has to be someone working to help these patients who have a high likelihood of death. That's how we got to that.

"With L.E.A.P.S.™ we can control in advance and determine, almost by design, how the immune system will process the epitope and therefore we know what kind of immune response we will get -- whether cellular or humoral. By doing that, you can -- we feel -- have significant impact on these people's chances of survival."

The complete special report authored by BioMedReport's M.E. Garza is available now at:

http://biomedreports.com/articles/most-p...

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fd...

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content -- including FDA and Clinical Trial Calendars.

For more biomedical sector and investment news, go to www.BioMedReports.com









Latest Releases
GILL Technologies Calls on the CRTC to Regulate Telecom Fraud
Gander Mountain Company Investor Alert: Takeover under Investigation
Aspect Medical Systems, Inc. Investor Alert: Takeover under Investigation
Affiliated Computer Services, Inc. board faces at least two lawsuits over takeover




© 2009 PR-CANADA.net
Joomla! is Free Software released under the GNU/GPL License.



Interesting sites: paris hotels, press releases